CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2018--
Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that Jill C. Milne, Ph.D.,
Chief Executive Officer, will present a corporate overview at
Oppenheimer’s 28th Annual Healthcare Conference on March 21,
2018 at 10:20am ET at the Westin New York Grand Central Hotel in New
York City, NY.
A webcast of the presentation will be available in the Investors section
of the Company’s website, www.catabasis.com,
and will be archived for 30 days following the presentation.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our SMART
(Safely Metabolized And Rationally Targeted) Linker drug discovery
platform enables us to engineer molecules that simultaneously modulate
multiple targets in a disease. We are applying our SMART LinkerSM
platform to build an internal pipeline of product candidates for rare
diseases and plan to pursue partnerships to develop additional product
candidates. For more information on the Company's drug discovery
platform and pipeline of drug candidates, please visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180320005309/en/
Source: Catabasis Pharmaceuticals, Inc.
Investor and Media Contact
Catabasis
Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
